Co-Partners
Associate Partners
Co-Partners
Associate Partners
May 20, 2019 03:50 PM IST
The company would continue to focus on R&D for some interesting pipeline of proprietary products.
May 17, 2019 03:50 PM IST
May 17, 2019 03:50 PM IST
May 17, 2019 09:27 AM IST
Narnolia Financial Advisors expects the pharma company to report a net profit of Rs 545 crore as against Rs 500 crore in the last quarter
May 15, 2019 02:40 PM IST
The company has launched its product, which is generic version of Merck Sharp & Dohme Corp's Cubicin, after obtaining approval from the US Food and Drug Administration (USFDA), the Hyderabad-based firm said in a statement.
May 06, 2019 12:52 PM IST
The company's testosterone gel 1.62 percent is a therapeutic equivalent generic version of AndroGel 1.62 percent of AbbVie Inc.
April 28, 2019 12:50 PM IST
Dr Reddy's Laboratories Inc, a subsidiary of the Hyderabad-based Dr Reddy's Laboratories, is voluntarily recalling the affected lot of bottles on account of certain deviations from the Current Good Manufacturing Practice (CGMP) regulations.
April 25, 2019 04:53 PM IST
Clopidogrel is an anti-platelet drug that blocks platelets from sticking together and prevents them from forming harmful clots.
April 17, 2019 03:15 PM IST
Net Sales are expected to increase by 7.7 percent Y-o-Y (down 1.1 percent Q-o-Q) to Rs. 3,807.5 crore, according to Kotak.
April 15, 2019 12:15 PM IST
Japanese brokerage house Nomura said the deal is positive both from a strategic as well as a financial perspective.
April 14, 2019 08:39 AM IST
The acquisition is in line with our stated strategy to significantly enhance our portfolio in our chosen growth markets, Dr Reddy's Laboratories CEO Erez Israeli said.
April 12, 2019 01:00 PM IST
Net Sales are expected to increase by 12.4 percent Y-o-Y (up 3.4 percent Q-o-Q) to Rs. 3,994.3 crore, according to Prabhudas Lilladher.
April 02, 2019 11:41 AM IST
REVLIMID (Lenalidomide) is indicated for treatment for multiple myeloma (cancer).
March 27, 2019 12:28 PM IST
"Dr Reddy's Tadalafil tablets are available in four strengths including 2.5 mg, 5 mg, 10 mg, and 20 mg, each in 30-count bottle size," Dr Reddy's Laboratories said in a BSE filing.
February 22, 2019 01:27 PM IST
In a regulatory filing Dr Reddy's said, "The audit of our formulations Shreveport plant, Louisiana, USA, by the United States Food and Drug Administration (USFDA) has been completed with zero observations".
February 21, 2019 04:40 PM IST
According to the latest Enforcement Report of the USFDA, the drug firm is recalling Levetiracetam in 0.54 percent Sodium Chloride injection, 1,500 mg/100 mL (15 mg/mL) single-dose infusion bags.
February 21, 2019 08:04 AM IST
Volatility in Dr Reddy's has shot up due to news flows. An Iron Condor trade to cash in on falling volatility going forward.
February 20, 2019 10:17 PM IST
Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, is a therapeutic equivalent generic version of Suboxone (buprenorphine and naloxone) sublingual film, Dr Reddy's said in a BSE filing.
February 20, 2019 02:54 PM IST
Dr Reddy’s generic Suboxone launch is set to be a reality. A much-awaited event, a mounting threat from competitors may limit its benefits
February 19, 2019 04:45 PM IST
ICICI Direct recommended hold rating on Dr Reddy’s Laboratories with a target price of Rs 2870 in its research report dated February 04, 2019.
February 18, 2019 10:33 AM IST
Majority of brokerage houses turned positive on the stock, advising buying after the USFDA issued EIR for Duvvada facility.
February 16, 2019 05:48 PM IST
This Duvvada facility in Andhra Pradesh was included in the warning letter received from USFDA in November 2015
February 12, 2019 11:31 AM IST
Quoting IMS Health data, Dr Reddy's Laboratories said, the Adcirca brand and generic had US sales of approximately USD 490 million for the most recent twelve months ending in November 2018.
February 08, 2019 10:11 AM IST
Of the 34 Nifty companies that have announced their earnings, 25 have either met or exceeded consensus estimates on both the PAT and EBITDA front
February 06, 2019 04:52 PM IST
The drug firm said it denies any wrongdoing and intends to vigorously defend against these claims.
Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.
